|
Volumn 32, Issue 4, 2002, Pages 581-583
|
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ENCODING RIBONUCLEASE L;
RIBONUCLEASE;
UNCLASSIFIED DRUG;
AGED;
ALLELE;
ARTICLE;
CANCER RISK;
CONTROLLED STUDY;
ENZYME ACTIVITY;
FAMILY HISTORY;
GENE;
GENE MUTATION;
HETEROZYGOSITY;
HOMOZYGOTE;
HPC1 GENE;
HUMAN;
MALE;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN VARIANT;
AGED;
AMINO ACID SUBSTITUTION;
ARGININE;
CASE-CONTROL STUDIES;
DNA MUTATIONAL ANALYSIS;
ENDORIBONUCLEASES;
GENE DELETION;
GENE DOSAGE;
GENETIC PREDISPOSITION TO DISEASE;
GERM-LINE MUTATION;
HETEROZYGOTE;
HOMOZYGOTE;
HUMANS;
MALE;
MIDDLE AGED;
PEDIGREE;
POINT MUTATION;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
|
EID: 18744388563
PISSN: 10614036
EISSN: None
Source Type: Journal
DOI: 10.1038/ng1021 Document Type: Article |
Times cited : (260)
|
References (12)
|